drugset / Trial / NCT00939211

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease

NCT00939211

Phase 2 Completed 25 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition with deteriorating lung function over the years. Patients with COPD experience symptoms of shortness of breath, cough and sputum production. This study is to assess the treatment effects after inhalation of three different single doses of AZD9164 (100, 400 and 1200 mcg) and one single dose of tiotropium (18 mcg). One dose of placebo will be given as comparator. 25 patients are to participate in the study and all will be recruited in Sweden. Each patient will visit the study doctor 9 times during the study, whereof 5 visits will be overnight visits. All examinations, treatment and the follow-up is free of charge.

Timeline

Start
2009-06
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9164 Small molecule 100 ug
Subject AZD9164 Small molecule 400 ug
Subject AZD9164 Small molecule 1200 ug
Comparator Tiotropium Other / unclassified 18 ug Inhaled